Table 1. Recipient demographic and pre-operative characteristics.
| Basiliximab (n = 78) | Steroid (n = 100) | P-value | |
| Gender | |||
| Female | 7 (9.0) | 15 (15.0) | 0.226¶ |
| Male | 71 (91.0) | 85 (85.0) | |
| Age | 48.7±8.4 | 49.6±8.9 | 0.485† |
| AFP1 | 207.0 (6.3, 897.3) | 200.0 (24.5, 1000.0) | 0.497‡ |
| Transplant year | |||
| 2003–2005 | 0 (0.0) | 79 (79.0) | <0.0001¶ |
| 2006–2009 | 78 (1.00) | 21 (21.0) | |
| Child–Pugh score2 | |||
| 5–6 | 40 (52.0) | 46 (46.0) | 0.211¶ |
| 7–9 | 33 (42.9) | 41 (41.0) | |
| 10–15 | 4 (5.2) | 13 (13.0) | |
| HCC | |||
| Primary cancer | 69 (88.5) | 93 (93.0) | 0.294¶ |
| Recurrent cancer | 9 (11.5) | 7 (7.0) | |
| HBV positive | 72 (92.3) | 92 (92.0) | 0.940¶ |
| HCV positive | 1 (1.3) | 2 (2.0) | 1.000§ |
| Cirrhosis | 68 (87.2) | 93 (93.0) | 0.190¶ |
| Number of tumors | 1.0 (1.0, 4.0) | 1.0 (1.0, 3.0) | 0.247† |
| Diameter of largest tumor (cm) | 3.8 (2.0, 7.0) | 4.0 (2.2, 8.5) | 0.479† |
| TNM tumor stage | |||
| Stage I | 15 (19.2) | 26 (26.0) | 0.135¶ |
| Stage II | 23 (29.5) | 38 (38.0) | |
| Stage III | 39 (50.0) | 36 (36.0) | |
| Stage IV | 1 (1.3) | 0 (0.0) | |
| Milan Criteria2 | |||
| Within Milan | 28 (36.4) | 36 (36.0) | 0.960¶ |
| Beyond Milan | 49 (63.6) | 64 (64.0) | |
| UCSF Criteria1 | |||
| Within UCSF | 31 (40.8) | 40 (41.2) | 0.953¶ |
| Beyond UCSF | 45 (59.2) | 57 (58.8) | |
| Diabetes mellitus | 3 (3.9) | 11 (11.0) | 0.079¶ |
| Hypertension | 6 (7.7) | 6 (6.0) | 0.655¶ |
| Hyperlipidemia | 3 (3.8) | 0 (0.0) | 0.082§ |
| Preoperative antiviral therapy | 16 (20.5) | 30 (30.0) | 0.151¶ |
Data are presented as number (percentage), median (IRQ), or mean ± standard deviation.
†
Independent t-test;
‡
Wilcoxon rank sum test;
¶
Chi-square test;
§
Fisher’s exact test.
1
Two subjects in basiliximab group and three in the steroid group were missing data.
2
One subject in basiliximab group was missing data.
AFP = alpha-fetoprotein; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; IQR = interquartile range; SD, standard deviation; UCSF, University of California San Francisco.